Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 11/20 | 0.35 |
| ▸ | ESR1 | P03372 | 5/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LSS | P48449 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8539247 | 0.80 | SMN1; SMN2 (0.50) | CYP3A4CYP2D6CYP2C9ALOX5SMN1; SMN2 | |
| SCHEMBL28977341 | 0.75 | KDM4E (0.33) | CYP3A4ALOX5SMN1; SMN2MITFALDH1A1 | |
| SCHEMBL251315 | 0.75 | ALDH1A1 (0.41) | CYP3A4SMN1; SMN2ALDH1A1 | |
| SCHEMBL28770396 | 0.72 | CYP3A4 (0.45) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10671966 | 0.71 | IDO1 (0.42) | CYP3A4CYP2C9ALOX5SMN1; SMN2ALDH1A1 | |
| SCHEMBL45130 | 0.71 | ESR1 (0.41) | ESR2ESR1ALOX5SMN1; SMN2ALDH1A1 | |
| SCHEMBL2919141 | 0.70 | ESR2 (0.43) | ESR2ESR1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1121965 | 0.70 | CYP2C19 (0.44) | CYP3A4CYP2D6CYP2C9ALOX5SMN1; SMN2 | |
| SCHEMBL3133878 | 0.69 | HTR2C (0.38) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL5886587 | 0.68 | ESR2 (0.56) | ESR2ESR1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220009882-A1 | ORGANOSULFUR COMPOUNDS | MARIPOSA THERAPEUTICS LTD. (GB) | 2022-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220009882-A1 | ORGANOSULFUR COMPOUNDS | F3, F2, TST | ACE 1576/4885ESR2 1989/4885ESR1 2311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.